by Usha Govindarajulu | Feb 4, 2022 | Biostatistics, Blog, COVID-19, New York, Professor, Usha Govindarajulu
February 2, 2022 A recent article in the Lancet Infectious Diseases presents a large scale study of post-vaccination infection conducted in the United Kingdom to assess potential long-haul symptoms. It was a prospective, community-based, nested, case-control study...
by Usha Govindarajulu | Jan 20, 2022 | Biostatistics, Blog, COVID-19, Professor, Usha Govindarajulu
January 18, 2022 A recent article in the New England Journal of Medicine (NEJM) presents results from a large cohort study from New York State on COVID-19 vaccine effectiveness. They used data for 8,690,825 adults in New York State to assess the effectiveness of the...
by Usha Govindarajulu | Dec 22, 2021 | Biostatistics, Blog, COVID-19, Usha Govindarajulu
The new variant of COVID-19, Omicron, and boosters from vaccines has been receiving a lot of press. In an article published in BMJ on December 14, 2021, “Covid-19: Omicron and the need for boosters”, the authors take us through a detailed summary about how a booster...
by Usha Govindarajulu | Dec 9, 2021 | Biostatistics, Blog, COVID-19, Usha Govindarajulu
December 9, 2021 The new variant for Omicron is causing a lot of stir around the world. Most of the data analysis conducted thus far has been preliminary and other planned data analyses are taking weeks in order to understand the potential severity of the variant and...
by Usha Govindarajulu | Nov 26, 2021 | Biostatistics, Blog, COVID-19, Healtcare, Professor, Usha Govindarajulu
At home Antigen tests statistical results November 24, 2021 Antigen tests for SARS-CoV-2 are back and are pending more approvals by the current administration. If so, they may be used more often and more frequently to help people get back to a more normal lifestyle....
by Usha Govindarajulu | Nov 10, 2021 | Biostatistics, Blog, Healtcare, Usha Govindarajulu
Pfizer anti-viral November 10, 2021 Pfizer, similar to Merck, has announced the efficacy of their anti-viral drug called PAXLOVID against SARS-CoV-2. The reported 89% efficacy against serious disease and 100% efficacy against death and they are making headlines....
